安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- One dose of experimental therapy reduced lipoprotein(a) more than 94% . . .
The medication, lepodisiran, is a small interfering RNA that reduces the production of Lp (a) in the liver by disabling messenger RNA that is involved in producing apolipoprotein (a), a key component in the Lp (a) particle
- Lepodisiran — A Long-Duration Small Interfering RNA Targeting . . .
To the Editor: Evidence about ethnic differences in the efficacy of antisense oligonucleotide therapies and of small interfering RNA (siRNA) therapies such as lepodisiran, the drug that was
- Lepodisiran - Wikipedia
Lepodisiran (LY3819469) is a small interfering RNA that was developed to reduce lipoprotein (a) in people at risk of cardiovascular disease It was developed by Eli Lilly and Company [1][2]
- ACC25: Positive results with Lillys Lp(a)-lowering drug
Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its
- Lepodisiran: A new cholesterol drug raising big questions
Explore physician reactions to Lepodisiran, an RNA-based cholesterol drug showing a 94% reduction in Lp (a) Physicians highlight key safety and efficacy concerns
- Lepodisiran, an Extended-Duration Short Interfering RNA Targeting . . .
Conclusions and relevance: In this phase 1 study of 48 participants with elevated lipoprotein (a) levels, lepodisiran was well tolerated and produced dose-dependent, long-duration reductions in serum lipoprotein (a) concentrations
- Single Dose of Lepodisiran Shows Promise in Lowering Lp(a) Over an . . .
A single subcutaneous injection of lepodisiran, an siRNA targeting mRNA for the LPA gene, substantially lowered lipoprotein (a), or Lp (a), below baseline levels for 48 weeks, according to new late-breaking science presented Nov 12 at AHA 2023 and simultaneously published in JAMA
- Lepodisiran for Elevated Lipoprotein (a) - JAMA Network
To the Editor In a recent randomized clinical trial, Dr Nissen and colleagues found that lepodisiran, an extended-duration short interfering RNA targeting lipoprotein (a), demonstrated high tolerability while decreasing serum lipoprotein (a) concentrations in a dose-dependent way over an extended period 1 These results were unexpected
|
|
|